Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Radiopharmaceutical Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GRP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRP Peptide / Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View GRP Products |
| Gene Delivery | GRP Promise-ORF / Lentivirus Full-length ORF for stable cell lines and expression validation. |
View GRP Products |
| Benchmark Ab | Anti-GRP Recombinant Antibody Recombinant positive control derived from clinical-grade sequences. |
View GRP Products |
| Validator | GRP siRNA Set For target knockdown and specificity verification. |
View GRP Products |
| Related Target A | GRPR (Gastrin Releasing Peptide Receptor) The primary G-protein coupled receptor mediating GRP oncogenic signaling. |
View GRPR Products |
| Related Target B | NMBR (Neuromedin B Receptor) Critical homolog target for off-target selectivity and counter-screening. |
View NMBR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Preservation | Lentiviral transduction vectors for stable GRPR overexpressing cell lines, bypassing VLP stability issues. |
| Subfamily Cross-Reactivity (NMBR/BRS3) | Sequence-verified homolog proteins and peptides for precise counter-screening panels. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target gene knockdown and functional verification. |
Live GRP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Gastrin-Releasing Peptide (GRP) and its cognate receptor (GRPR) system is undergoing a major paradigm shift. Historically evaluated as an autocrine growth factor in small cell lung cancer (SCLC), the GRP/GRPR axis has emerged as a premier target for radiopharmaceutical development, particularly in prostate and breast cancers.
The race for GRP therapeutics is intensifying, with major players shifting focus from traditional antagonist peptides to radioligand conjugates (RLTs) and peptide-drug conjugates (PDCs). As first-generation diagnostic imaging agents establish clinical utility, the next wave of R&D is targeting therapeutic radioligand alpha/beta emitters and bispecific constructs designed to maximize tumor retention while minimizing gastrointestinal side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Radioligand Therapy (RLT) | Novartis, Advanced Accelerator Applications | Prostate Cancer, Breast Cancer | High-purity GRPR-expressing target cells (Lentivirus-driven) for internalization assays. |
| Peptide-Drug Conjugate (PDC) | Bicycle Therapeutics, PeptiDream | Solid Tumors (SCLC, PRCC) | High-affinity GRP/GRPR binding validation with sequence-verified recombinant proteins. |
| Monoclonal Antibodies / ADCs | Academic Institutes, Biotech Startups | Small Cell Lung Cancer | In vitro internalization and antibody-dependent cellular cytotoxicity (ADCC) assays. |